Skip to search formSkip to main contentSkip to account menu

Remsima

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
Immune-mediated inflammatory diseases share several pathogenic pathways and this pushes sometimes to extrapolate from one disease… 
2019
2019
Comparative Cost Efficiency of the Originator Drug of Infliximab and its Biosimilar for the Treatment of Rheumatoid Arthritis in the MENA Region
Objectives: To study and assess the comparative cost efficiency of Infliximab’s originator (Remicade®) and its biosimilar… 
2016
2016
Drivers of costly treatment strategies in rheumatoid arthritis
2016
2016
AB0310 Prospective Study of 78 Patients Treated with Infliximab Biosimilar Remsima®
Background In 2015 it began to be used in many EU countries the first biosimilar antiTNF (Infliximab) approved by the EMA. The… 
2016
2016
PTH-082 Comparison of Efficacy and Safety of Biosimilar Infliximab to Originator Infliximab in Children with Inflammatory Bowel Disease
Introduction CT-P13 is the biosimilar Infliximab approved for use in Europe and it is marketed in the UK in two brand names… 
2016
2016
CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease.
2016
2016
OP0015 Antibodies To Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity towards Biosimilar CT-P13
Background The first infliximab (IFX) biosimilar (CT-P13) in Europe is marketed as two brand names, Inflectra (IFT) and Remsima… 
2015
2015
A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases
The development of biologic drugs has undoubtedly enhanced the spectrum of treatments available for immune-mediated inflammatory… 
2014
2014
Biosimilar drugs, myths and reality.
2014
2014
Biosimilar monoclonal antibodies approved for use in the EU
Two biosimilar TNF-alfa monoclonal antibody (mAb) products were approved for clinical use in the European Union on 10 September… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)